<DOC>
	<DOCNO>NCT01410448</DOCNO>
	<brief_summary>The purpose study evaluate whether delayed ( i.e . 28 ± 4 day post-transplant ) administration everolimus transplantation reduces risk wound heal complication comparison immediate administration de novo renal transplant patient ( proportion patient without wound/surgical complication relate initial transplant surgery ) randomization 3 month transplantation</brief_summary>
	<brief_title>Everolimus de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criterion : Patients willing able participate study provide write informed consent perform study related procedure ; Men woman ≥18 year transplant ; Recipients 1st 2nd single kidney transplant decease donor living unrelated/related donor &gt; 14 year ; Exclusion criterion : Patients recipient multiple organ transplant , include two kidney ; Historical current peak PRA &gt; 50 % . Patients already exist antibody donor ; Thrombocytopenia ( platelet &lt; 75,000/mm³ ) , absolute neutrophil count &lt; 1,500/mm³ , leucopenia ( leucocytes &lt; 2,500/mm³ ) hemoglobin &lt; 7 g/dL ; Body mass index ( BMI ) &gt; 30 Kg/m2 ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>safety</keyword>
</DOC>